# DePuy Synthes

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/depuy-synthes
Canonical HTML page: https://getbiobrief.com/entity/depuy-synthes

## Timeline

- **2026-03-12**: BofA Price Target Hike — Bank of America increases price target, highlighting R&D productivity and MedTech growth.
- **2026-03-07**: Fast-Track Approval — USFDA grants approval for Tecvayli-Darzalex combination via fast-track voucher program.
- **2026-03-05**: 12-Month High — JNJ shares reach a new yearly peak following FDA approval for multiple myeloma combo.

## Recent coverage (1 stories)

### BofA Bullish on Johnson & Johnson as Pipeline Momentum Accelerates
2026-03-12 08:11:42 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Bank of America has raised its price target for Johnson & Johnson, citing a robust outlook for the company's Innovative Medicine and MedTech divisions. The upgrade reflects growing confidence in JNJ's oncology pipeline and its ability to navigate upcoming patent expirations for key assets.
Full story: https://getbiobrief.com/story/bofa-jnj-price-target-pipeline-growth

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.